The
right
assay.
Done
right.
Our mission is to accelerate our partner's research programs by developing and executing predictive and scalable assays to quantify the bioactivity of novel chemical and biological entities.
We combine scientific rigor with our domain expertise in laboratory automation, informatics, and industry best practices to turn challenging assays into quantitative, reproducible results.
Our services
Our partners
2bind
2bind is a provider for biophysical analytical services operating in a fee-for-service business model. Our broad portfolio of biophysical assays for hit identification, validation and characterisation allows our customers to accelerate and streamline key research processes in their early drug discovery programs.
anteris medical
Anteris medical supports the pharmaceutical, biotech and medical device industries globally by managing the development of combination products, medical devices or in vitro diagnostics. Our broad competencies cover compliance, regulatory affairs combined with innovative, resource-efficient solutions for compliant development and technical documentation as well as marketing and sales expertise.
ISAR Bioscience GmbH
ISAR is a translational research company dedicated to overcoming current limitations of stem cell research to advance discovery of novel therapeutics and industrial biotechnology products. We combine human iPSC and genome engineering technologies to build the next generation of disease models for therapeutics discovery and cell-based models for industrial biotechnology applications. ISAR forges strategic partnerships with industry partners to translate scientific breakthroughs into industrial solutions and products.
Metrion Biosciences
Metrion Biosciences is an ion channel focused CRO offering integrated drug discovery services, CiPA compliant cardiac safety profiling, phenotypic assays, translational assays and custom screening services on a fee-for-service or collaboration basis. Metrion’s know-how and breadth of services adds value to drug discovery programs by developing and de-risking ion channel modulators as they progress towards nomination for clinical development.
Nanion Technologies
Nanion is a leading provider of automated patch clamp systems with throughput capabilities ranging from a single cell up to fully automated high throughput screening instruments recording from 384 cells simultaneously. Our portfolio contains furthermore analysis devices for membrane pump and transporter recordings (SURFE²R), bilayer recordings (Orbit), and cell monitoring/contractility measurements (CardioExcyte 96).
News
Assay-ready TRP-Channel Cells as a Tool for Drug Discovery
Transient receptor potential (TRP) channels are important targets for discovering novel drugs in a variety of indications, including neuropathic pain or cancer. Together with our partners AcCELLerate and Nanion, we established the pharmacology of recombinant cell lines expressing TRPA1, TRPM8, TRPV1, TRPV3, or TRPV4, in a fluorescent Ca2+-flux assay as well as automated patch-clamp. The cell lines are available as assay-ready frozen cells and can be used directly after thawing for substance screening or profiling of lead candidates.
Nanion and Assay.Works partner to offer SURFE²R assays "As-a-Service"
Backed by Nanion’s electrophysiology expertise, Assay.Works provides comprehensive assay services for the SURFE²R 96SE platform. The offering adds an economic, low-risk option for researchers seeking predictive assays for membrane transporters.
Assay.Works named a 2019 Top-Performing Provider on ScienceExchange!
Science Exchange, a leading R&D services marketplace, selected Assay.Works as one of the top-performing service providers for High-Throughput Screening based on responsiveness, productivity, and requester endorsements. Get the » ebook to view the complete list.
Teaming up with ISAR Bioscience to advance discovery of novel therapeutics in the fields of regenerative medicine.
Assay.Works and ISAR Bioscience signed a collaboration agreement to use state-of-the-art stem cell technologies for the development of new therapeutics with an initial focus on neurodegenerative disorders.
About Us
Assay.Works builds on the legacy of the HTS Center of a leading biopharmaceutical company where we provided assay, screening, and quantitative biology services for drug discovery programs across therapeutic areas with high medical need. During our 16-year tenure, we developed and implemented more than 250 screens spanning all major drug target classes, and generated over 100,000,000 data sets.
Dr. Ralf Schwandner
Founder and CEO
Biologist and seasoned Lead Discovery specialist with 18 years of experience in the biopharmaceutical industry. Prior to founding Assay.Works, he served as head of Amgen‘s HTS center of excellence at Regensburg, Germany (Amgen Research GmbH).
Dr. Johannes Knop
Founder and COO
Biochemist with 16 years of industry experience in Lead Discovery. Most recently, he was head of Research Operations at Amgen Research GmbH, where he managed Sample Management, cell-based Lead Profiling, Cell Production, Informatics, and EH&S.
Contact Us
please enable javascript to view
Assay.Works GmbH
Am BioPark 11
93053 Regensburg
Germany
T +49 941 2000 1240
F +49 941 2000 1241
please enable javascript to view
www.assay.works